Related Experiment Video
Updated: Mar 7, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Personalized medicine in interstitial lung diseases
Paolo Spagnolo1, Justin M Oldham, Mark G Jones
1aDepartment of Cardiac, Thoracic and Vascular Sciences, Section of Respiratory Diseases, University of Padova, Padova, Italy bDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, The University of California at Davis, Sacramento, California, USA cNational Institute for Health Research Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, University of Southampton, Southampton, UK dDepartment of Medicine, University of Colorado Denver, Aurora, Colorado, USA.
Personalized medicine shows promise for interstitial lung diseases (ILDs), especially idiopathic pulmonary fibrosis (IPF). Identifying patient subgroups could improve prognostication and treatment strategies for ILDs.
Area of Science:
- Pulmonary Medicine
- Genetics
- Personalized Medicine
Background:
- Interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are increasingly explored for personalized medicine applications.
- IPF is the most common and fatal form of idiopathic interstitial pneumonias.
Purpose of the Study:
- To review and discuss recent literature on personalized medicine in IPF, hypersensitivity pneumonitis, and sarcoidosis.
- To highlight patient subgroups where personalized prognostication and management are feasible.
Main Methods:
- Literature review of recent studies on personalized medicine in ILDs.
- Analysis of studies focusing on IPF, hypersensitivity pneumonitis, and sarcoidosis.
Main Results:
- Studies in IPF suggest distinct subgroups based on genetics, molecular pathways, exposures, and lifestyle.
- Personalized medicine for hypersensitivity pneumonitis is nascent.
- Applying personalized medicine to sarcoidosis faces challenges like lack of diagnostic standards and variable disease courses.
Conclusions:
- Identification of distinct patient subgroups in ILDs holds potential for predicting disease behavior and treatment response.
- Further validation of identified subgroups is necessary for clinical application in ILDs.
